Under a pure market approach, if a drug is not profitable it will not be produced ans sold. If you have a rare disease, you would probably prefer a mixed approach like a mix public and private medical research.
Imagine you have only pure market that provides 80% total availability for disease remedies. If you want to cover the 20% uncovered case by bringing a non-profit player, you may threaten some of the pure market player. At the end you may have a 60% coverage by for-profit and 40% by non-profit.
The end solution may seems to be less economically efficient but it covers more of the population and I think it is a good thing.